Institute for Clinical and Economic Review’s “new evidence update” on PCKS9 inhibitors highlights lack of mortality benefit with evolocumab

13 June 2017 - Newly released clinical trial data show expected reductions in stroke and heart attack, but mortality benefit ...

Read more →